This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Click here to see the original post from April 2025. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. All rights reserved.
Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Drawing from DCIs new 2025 Economic Report on U.S. Today, we dive deeper. All rights reserved.
Threes still company in the world of pharmacy benefit managers. Below, we break down the latest market share data from Drug Channels Institute (DCI), explore the developments driving these changes, and examine what they signal for the future of the PBM landscape. P.S. Special launch pricing on our new 2025 Economic Report on U.S.
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Click here to see the original post from March 2025. Three’s still company in the world of pharmacy benefit managers. All rights reserved.
The 340B Drug Pricing Program has emerged as a growing source of profits for pharmacies and pharmacy benefit managers (PBMs). pharmacy industry—function as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. It was meant to be part of patient care.” Fein, Ph.D.,
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate, and Disruption. Click here to see the original post from March 2025. Next week, Drug Channels Institute (DCI) will release our 2025 Economic Report on U.S. All rights reserved.
During my recent Drug Channels Outlook 2025 video webinar, I tackled a wide range of crucial topicsincluding the controversial 340B Drug Pricing Program. As I explain in this video excerpt, we may finally see reform of this rapidly expanding program.
Small pharmacies have ghosted Medicare Part Ds preferred networksno farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Abracadabra!
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: Whats Next for Retail Pharmacy: Data, Debate, and Disruption This event will be broadcast live on: Friday, June 20, 2025 12:00 p.m. It is part of The Drug Channels 2025 Video Webinar Series.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCIs new live video webinar: PBM Industry Update: Trends, Challenges, and What's Ahead This event will be broadcast live on Friday, April 4, 2025, from 12:00 p.m. This event is part of The Drug Channels 2025 Video Webinar Series.
Click here to see the original post from January 2025. For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. What do you think? All rights reserved.
The 2025 launch of biosimilars to Johnson & Johnson’s Stelara (ustekinumab) marks another turning point in pharmacy benefit dynamics. But unlike the chaotic rollout of Humira biosimilars, pharmacy benefit managers (PBMs) came prepared. As always, with great pricing power comes great responsibility. All rights reserved.
I am pleased to announce that Drug Channels Institutes new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Drug Channels Institutes (DCIs) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. DCI has identified nearly 1,900 dispensing locations with specialty pharmacy accreditation. Once again, specialty mostly means affiliated with a PBM. What do you think?
Informa Connect’s Trade and Channel Strategies December 10-12, 2024 at the W Hotel in Philadelphia, PA Drug Channels readers save 10% with code 24DC10 * Pharmacy and distribution models are growing increasingly complex. Stop running in circles—It’s time to unlock proven strategies to propel market access. What is the secret to success?
This week, Im rerunning some popular posts while I prepare for todays Drug Channels Outlook 2025 live video webinar. (If As you will see below, CMS projects that outpatient prescription drugs dispensed by retail and mail pharmacies will remain a small share of total U.S. If you sign up before 12 p.m. ET, you can attend the live event.)
There was more bad news, as employment in retail pharmacies and drugstores dropped by 8,500 positions in 2024, following a drop of 4,800 positions in 2023. Employment in mass merchants and supermarkets with pharmacies increased. Click here to share your thoughts on the pharmacist job market with the Drug Channels LinkedIn community.
Todays guest post is from Divya Iyer, SVP of Go-to-Market Strategy at GoodRx. Divya shares new GoodRx data showing that out-of-pocket costs at the pharmacy counter remain a primary barrier to medication adherence. To learn about GoodRxs prescription abandonment solutions, download Reduce Rx Abandonment at the Pharmacy.
Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3 In the U.S.,
He holds a master’s degree from University of Salerno in political sciences and marketing. He holds a PhD in pharmacy from the University of North Carolina at Chapel Hill, and an MBA from the Rochester Institute of Technology. The Rise of Multimodal Language Models in Drug Development (2025).
You'll learn how money and medicines move between manufacturers, wholesalers, pharmacies, PBMs, and payersand how each relationship affects costs and outcomes. The Economics of Retail, Mail, and Specialty Pharmacies Gain a clear-eyed view of how different pharmacy channels generate revenue and manage costs. All rights reserved.
I could not find, that it hath, or ever had, any place in pharmacy, or any fuch qualities, as I fufpected afcribed to it by the botanifts. NSAID Expansion: 1949 to present While it is seemingly impossible to find figures for aspirin consumption or production over time, it is clear that it took off after Bayer began marketing the drug in 1899.
SPA allows sponsors to gain regulatory perspective on whether a proposed trial design is adequate to support a marketing application, though the ultimate approval decision is based on the data submitted for review. This study is planned to start in late 2024 and conclude in late 2025.
On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year. Final Guidance at 2. 1395w-114c(b)(4)(B)(i).
The Agenda also includes several long-term actions expected to take place in 2024 and 2025 – included as part of FDA’s long-term regulatory agenda. The rule, will also, if finalized, address communication with State boards of pharmacy. The anticipated date of publication is June 2023, meaning we should see this regulation imminently.
WUSF / AgencyIQ November 1 Initial deadline for NDSRIs Under a 2023 guidance document, the FDA has recommended that pharmaceutical companies assess Nitrosamine Drug-Related Substance Impurities for their products by November 1, 2023, with confirmatory testing due by August 1, 2025. the drug and device) of the combination product.
CDER, CBER Draft 12/29/2025 FDA must issue final guidance no later than 18 months after the close of the public comment period for draft guidance. Priority A List. use of RWE, registries) for capturing post-approval safety and efficacy data for cell and gene therapy products.
As I predicted, the stand-alone Medicare Part D prescription drug plans (PDP) market is vanishing. For 2025, DCI’s exclusive analysis of Center for Medicare & Medicaid Services’ (CMS) data reveals that the number of PDPs will drop to a historic low. What else should you expect for 2025? Legislate in haste. Repent in leisure.
In Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market , I documented the Inflation Reduction Act’s (IRA) disruption to Medicare Part D prescription drug plans (PDPs). As always, we provide you with a handy table for tallying each chain’s participation and changes from 2024 to 2025.
Next week, Drug Channels Institute (DCI) will release our 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. For 2024, DCI estimates that total prescription dispensing revenues at retail, mail, long-term care, and specialty pharmacies reached $683 billion, up 9% from the 2023 figure. to 1:30 p.m.
For 2025, the three largest pharmacy benefit managers (PBMs)Caremark (CVS Health), Express Scripts (Cigna), and Optum Rx (United Health Group)have again each excluded hundreds of drugs from their standard formularies. In fact, nearly all marketed Humira biosimilars are excluded from the larger PBMs 2025 formularies.
This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. In the video excerpt below, I walk through a brief history of 340B contract pharmacies. I conclude with a follow the dollar example of 340B prescription economics with contract pharmacies. All rights reserved.
From catch-all to calibrated: A more targeted approach to pharma DTC marketing Explore how pharma marketers can optimize impact by leveraging pharmacy retail media to reach high-intent audiences. Discover ways to boost first-fill and refills while maximizing marketing spend.
Comments on the proposed order are due May 25, 2025. Nor does it allow for full consideration of the implications of removing PE from the monograph and leaving pseudoephedrine as the only oral decongestant active ingredient that can be used in an OTC drug marketed under the monograph.
Informa Connect's Access USA March 18-20, 2025, Pre-Event Workshops on March 17 Drug Channels readers save 10%* on their registration with code 25AUSA10 Three events. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. The future of patient access. Which event is for you? All rights reserved.
He holds a masters degree from University of Salerno in political sciences and marketing. He holds a PhD in pharmacy from the University of North Carolina at Chapel Hill, and an MBA from the Rochester Institute of Technology. 2024 [cited 2025 Feb 7]. Velez (2025). Lifescienceleader.com. doi: 10.1016/j.drudis.2024.104009.
The operational impact of xAI is substantial, especially given that 37 percent of the market views the explanation of results from GenAI algorithms as a strategic priority that goes beyond regulatory compliance. He holds a masters degree from University of Salerno in political sciences and marketing. 2024 [cited 2025 Feb 7].
As an initial matter, the Federal Food, Drug, and Cosmetic Act (FDC Act) precludes the importation of unapproved prescription drug products, including versions of FDA-approved drugs intended for distribution in foreign markets like the EU. Unapproved prescription drugs present serious safety and effectiveness concerns.
president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2025 This event will be broadcast live on Friday, December 13, 2024, from 12:00 p.m. Fein, Ph.D., to 1:30 p.m. Or, just click here to order.)
Published June 12, 2025 Amy Baxter Staff Reporter post share post print email license Win McNamee via Getty Images First published on The budget bill currently under consideration in Congress is big — and it’s complicated. By Jacob Bell • May 6, 2025 Keep up with the story. But the bill’s path forward is uncertain.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content